𝔖 Bobbio Scriptorium

✦ LIBER ✦

Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma—Mechanistics, review of phase III randomized clinical trials, and regulatory implications

✍ Scribed by Eskander, Ramez N.; Tewari, Krishnansu S.

Book ID: 121468991
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 822 KB
Volume: 132
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2013.11.029

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase III randomized trial of BAY 12-9

A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study

✍ H. Hirte; I.B. Vergote; J.R. Jeffrey; R.N. Grimshaw; S. Coppieters; B. Schwartz; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 276 KB

127Immediate hormonal therapy improves l

127Immediate hormonal therapy improves locoregional control and survival in patients with locally advanced prostate cancer. Results of a randomized phase III clinical trial of the eortc radiotherapy and genito-urinary tract cancer cooperative groups

✍ Bolla, M.; Gonzelez, D.; Warde, P.; Dubois, J.B.; Mirimanoff, R.; Storme, G.; Be 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 105 KB